LB Pharmaceuticals Inc LBRX

Set alert

Price alert · LBRX

All alert types
40.65 USD +1.61 +4.11%

As of Nov 3, 1:03 PM ET

Bid
40.53 × 2
Ask
40.73 × 2
39.15 Day range 41.40
14.32 52-week range 50.16
YTD
+82.59%
1 year
+151.36%
Open
39.65
Prev close
39.04
Mkt cap
1.31B
Vol
78.06K
Avg vol
361.92K
EPS
0.10
P/E
406.45
Div yield
0.00%
More statistics
Low
39.15
High
41.40
Forward P/E
-7.26
Beta
0.00
Short ratio
12.64
Inst. own
102.44%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
41.38
200-d avg
32.57
1y target
58.00

MAX chart

Chart tools
Interval

Chart is warming up

The all-time price history for LBRX has not been loaded yet. Try again in a moment.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 58.00 +42.7% upside
Target (low)
35.00
Target (mean)
58.00
Target (high)
80.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy8
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 11
  • 1 month ago 8
  • 2 months ago 8

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

LBRX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-1.52-1.74 – -1.07-0.61-149.2%00.0%8
Next quarter-1.52-1.81 – -1.15-0.45-238.3%00.0%8
Current year-5.47-5.93 – -4.63-3.13-74.9%00.0%9
Next year-5.13-6.41 – -4.14-5.47+6.3%00.0%9

Upgrades and downgrades

The latest rating changes

LBRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 9, 2026Canaccord GenuityInitiated—Buy
Oct 6, 2026GuggenheimInitiated—Buy
Oct 5, 2026Roth CapitalDowngradeBuyNeutral
Oct 2, 2026NeedhamInitiated—Buy
Aug 24, 2026HC Wainwright & Co.MaintainedBuyBuy
Aug 12, 2026BMO CapitalMaintainedOutperformOutperform
Aug 3, 2026HC Wainwright & Co.ReiteratedBuyBuy
Jul 21, 2026BMO CapitalInitiated—Outperform
Jul 7, 2026Wolfe ResearchInitiated—Outperform
Apr 27, 2026HC Wainwright & Co.Initiated—Buy
Apr 10, 2026Craig-HallumInitiated—Buy
Mar 27, 2026StifelMaintainedBuyBuy
Dec 11, 2025StifelMaintainedBuyBuy
Oct 6, 2025StifelInitiated—Buy
Oct 6, 2025Piper SandlerInitiated—Overweight
Oct 6, 2025Leerink PartnersInitiated—Outperform